MD Anderson research: combination therapies for BRAF V600E mutations, cancer biomarkers in extracellular vesicles, and strategies for overcoming treatment resistance in lung cancer and AML

Researchers develop antibody-toxin conjugate to boost immune response against cancer

Researchers at the University of Texas MD Anderson Cancer Center have developed a novel antibody-toxin conjugate designed to stimulate immune-mediated eradication of tumors.

February 28, 2025

Vol.51 No.08

Clinical Roundup

New biomarker can predict cancer aggressiveness, study finds

Researchers from Fred Hutch Cancer Center and the University of Texas MD Anderson Cancer Center have uncovered a biomarker capable of accurately predicting outcomes in meningioma brain tumors and breast cancers using a new technology and computational method.

February 21, 2025

Vol.51 No.07

Drugs & Targets

FDA grants priority review to Boehringer’s BI 1810631 for the treatment of HER2-mutant advanced NSCLC

FDA granted priority review to Boehringer Ingelheim’s new drug application for BI 1810631 (zongertinib) for the treatment of adult patients with unresectable or metastatic non-small cell lung cancer whose tumors have HER2 mutations and who have received prior systemic therapy.

February 21, 2025

Vol.51 No.07

Cancer History Project Podcast

20 years of EGFR research: Ramalingam, Carbone, Politi, Jänne, Govindan reflect

Two decades ago, the discovery of the EGFR mutation transformed lung cancer treatment. The finding led to dramatically improved survival rates and ushered in the era of precision medicine and molecular profiling for lung cancer.

February 14, 2025

Vol.51 No.06

By Yiqing Wang

ACS report: Cancer mortality continues to drop despite rising incidence in women

Despite steady progress in reducing overall cancer mortality rates, cancer incidence in women is rising, according to the American Cancer Society’s “Cancer Statistics, 2025” report. Incidence rates in women 50-64 years of age have surpassed those in men, and rates in women under 50 are now 82% higher than their male counterparts, up from 51% higher in 2002. In 2021, for the first time, lung cancer incidence was higher in women under 65 than in men.

January 17, 2025

Vol.51 No.02

By Yiqing Wang

Clinical Roundup

ctDNA levels linked to recurrence risk in lung cancer, study finds

Personalis, Inc., in collaboration with professor Charles Swanton and his colleagues at London’s Francis Crick Institute and University College London, published new results from their TRACERx lung cancer study in Nature Medicine.

January 17, 2025

Vol.51 No.02

MD Anderson research: combination therapies for BRAF V600E mutations, cancer biomarkers in extracellular vesicles, and strategies for overcoming treatment resistance in lung cancer and AML

YOU MAY BE INTERESTED IN

Researchers develop antibody-toxin conjugate to boost immune response against cancer

New biomarker can predict cancer aggressiveness, study finds

FDA grants priority review to Boehringer’s BI 1810631 for the treatment of HER2-mutant advanced NSCLC

20 years of EGFR research: Ramalingam, Carbone, Politi, Jänne, Govindan reflect

ACS report: Cancer mortality continues to drop despite rising incidence in women

ctDNA levels linked to recurrence risk in lung cancer, study finds

Renew today!

Subscriber content

Never miss an issue!

Login